NEW YORK – Turning Point Therapeutics on Thursday said it has garnered an exclusive license to develop and commercialize LaNova Medicines' Claudin18.2-targeting antibody-drug conjugate, LM-302, worldwide, excluding greater China and South Korea.
Turning Point paid Shanghai-based LaNova $25 million upfront for the rights to the drug, which will be renamed TPX-4589. LaNova is also eligible to receive an additional $195 million in development and regulatory milestone payments, as well as commercial sales milestones and tiered royalties in the mid-single digit to mid-teens percentages on net sales of the drug. The companies also have the option to expand their partnership and advance three other antibody-drug conjugate programs.
This is the first drug San Diego-based Turning Point has in-licensed. The agent is currently being evaluated in several early-stage studies in the US and in China, exploring TPX-4589 in a variety of Claudin18.2-positive advanced solid tumors.
The drug, which was discovered by LaNova, has demonstrated efficacy in gastric and pancreatic cancer xenograft models. Claudin18.2 is expressed in around two-thirds of patients with these types of cancers.
"Claudin18.2 is continuing to emerge as an important target," Turning Point CEO and President Athena Countouriotis said in a statement. "We chose TPX-4589 based on it potentially being a first-in-class antibody-drug conjugate to target Claudin18.2 and its preclinical data that show the potential to target tumors with low and high expression levels, which we believe could be an important differentiator versus other investigational therapies."